title: Repp86: a new prognostic marker in mantle cell lymphoma.
abstract: OBJECTIVE
  Proliferation indices are important prognostic factors for the clinical outcome of patients with mantle cell lymphoma (MCL). We investigated whether the expression of repp86 (restrictedly expressed proliferation-associated protein 86 kDa), a new proliferation specific marker expressed in the cell cycle phases G(2), S and M, but not in G(1), correlates with the clinical course in patients with MCL.
  
  
  METHODS
  Biopsy specimens from 94 untreated patients enrolled in two multicenter trials were investigated immunohistochemically with monoclonal antibodies against CD20, CD5, CD3, CD23, cyclin D1, and repp86 (Ki-S2).
  
  
  RESULTS
  Patients with 0-1% repp86 expression had a median overall survival time of 71.0 months, compared with 38.2 months for patients with 1-5% positive cells and 25.4 months for patients with 5-10% positive tumor cells. Patients with repp86 expression of more than 10% showed the shortest survival (median: 15.0 months). Kaplan-Meier analysis revealed a significant difference in the overall survival time between patients with very high (>10%) and very low (0-1%) repp86 expression (P < 0.0001) in the tumor cells. The multivariate analysis revealed repp86 expression to be superior to other clinical characteristics as a prognostic factor (P = 0.0016).
  
  
  CONCLUSIONS
  Based on these findings, repp86 expression is a new important prognostic factor in MCL.
authors.affiliation: II. Department of Internal Medicine and Hematology, University Hospital of Schleswig-Holstein, Campus Kiel, Germany. cschrader@med2.uni-kiel.de
authors.forename: Carsten
authors.initials: C
authors.lastname: Schrader
authors.forename: Dirk
authors.initials: D
authors.lastname: Janssen
authors.forename: Peter
authors.initials: P
authors.lastname: Meusers
authors.forename: Günter
authors.initials: G
authors.lastname: Brittinger
authors.forename: Jens U
authors.initials: JU
authors.lastname: Siebmann
authors.forename: Reza
authors.initials: R
authors.lastname: Parwaresch
authors.forename: Markus
authors.initials: M
authors.lastname: Tiemann
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001706:Biopsy / Q000379:methods; D002453:Cell Cycle; D018572:Disease-Free Survival; D004720:Endonucleases; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D020522:Lymphoma, Mantle-Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009687:Nuclear Proteins / Q000096:biosynthesis*; D011379:Prognosis
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D004720:Endonucleases; C095221:SND1 protein, human